-
No Ligand, No Kinase, No Problem(Post)
HER2 has no ligand. HER3 has no kinase. Together they are the most potent signalling pair in human biology. That single sentence explains most of what is strange about this receptor family and all of
Dendritic Cells - Markers, Activation & Subtypes(Post)Immunology · Antigen PresentationDendritic Cells: Markers, Activation and SubtypesDendritic cells are the professional antigen-presenting cells that decide whether an immune response happens at all. T
Elotuzumab: Revolutionizing Multiple Myeloma Treatment and Research Applications(Post)Quick Facts About ElotuzumabWhat is Elotuzumab?Elotuzumab is a monoclonal antibody designed to enhance the immune system's ability to detect and destroy multiple myeloma cells. It target
Brodalumab: A Breakthrough in IL-17 Receptor Blockade for Psoriasis and Beyond(Post)Quick Facts About BrodalumabWhat is Brodalumab?Brodalumab is a monoclonal antibody that targets the IL-17 receptor to treat immune-mediated conditions like moderate-to-severe plaque psor
Erenumab: Transforming Migraine Prevention Through CGRP Receptor Inhibition(Post)Quick Facts About ErenumabWhat is Erenumab?Erenumab is a fully human monoclonal antibody designed to prevent migraines by targeting the calcitonin gene-related peptide (CGRP) receptor.
Targeting CD200: Unlocking Immune Suppression in Tumors(Post)Immune evasion is one of the hallmarks of cancer, where tumor cells employ various strategies to suppress immune responses and prevent destruction by the body’s defense systems. CD200, a
Belimumab: Unveiling Its Role in Lupus and Beyond(Post)Quick Facts About BelimumabWhat is Belimumab?Belimumab is a monoclonal antibody used to treat systemic lupus erythematosus (SLE), an autoimmune disease. It is marketed under the brand na
Polatuzumab: Redefining Targeted Therapies in B-Cell Lymphoma(Post)What You Need to Know About PolatuzumabWhat is Polatuzumab??Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, a component of the B-cell receptor, used primarily in B-cel
Ladiratuzumab Vedotin: Targeting TNBC with Next-Gen ADC Therapy(Post)Quick Facts About Ladiratuzumab VedotinWhat is Ladiratuzumab Vedotin?Ladiratuzumab Vedotin is an antibody-drug conjugate (ADC) designed to target LIV-1, a protein commonly expressed in t
Ramucirumab: Mechanism, Clinical Applications, and Biosimilars in Cancer Research(Post)Quick Facts About RamucirumabWhat is Ramucirumab?Ramucirumab is a monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR-2), inhibiting angiogenesis, a pro
Vopratelimab: Unlocking the Potential of ICOS in Cancer Research(Post)What You Need to Know About VopratelimabWhat is Vopratelimab?Vopratelimab is an experimental monoclonal antibody that targets the Inducible T-cell CO-Stimulator (ICOS) protein, playing a
Avizakimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther
Tomaralimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat
Lusvertikimab: Unveiling the Potential in Immuno-Oncology(Post)What You Need to Know About LusvertikimabWhat is Lusvertikimab?Lusvertikimab is a monoclonal antibody designed to inhibit the IL-4 receptor, a key player in regulating immune responses,
Uliledlimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About UliledlimabWhat is Uliledlimab?Uliledlimab is a monoclonal antibody targeting CD47, a checkpoint protein that helps tumors evade immune system detection. By blocking CD
AACR 2025 - Scientific Progamme, Venue and Exhibits(Post)AACR 2025: Meet Assay Genie at the American Association for Cancer Research Assay Genie is delighted to be attending and exhibiting at AACR 2025 in Chicago, Illinois from the 25-30th of
MAPK Signaling in Inflammatory Cytokines Pathways(Post)Cell Signalling · InflammationMAPK Signalling in Inflammatory Cytokine PathwaysMAPK cascades convert receptor engagement into changes in gene expression, and in inflammation they do it in both directi
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest
Exhibition at the University of Oxford's BioEscalator(Post)Showcasing Innovation Assay Genie recently took part in an engaging event at Oxford’s BioEscalator, a leading innovation hub supporting scientific progress and entrepreneurship. The day
Targeting VISTA: Unleashing the Power of T Cells in Cancer Therapy(Post)V-domain Ig suppressor of T cell activation (VISTA) is an emerging immune checkpoint receptor that plays a key role in suppressing T cell activity within the tumor microenvironment (TME).